Did anyone catch the RadioWallStreet show on Wednesday? There, Joseph Besecker, President of Emerald Research, http://www.radiowallstreet.com/Columnist.cfm?CompanyID=241 forecast the TRMS to rise to $28.00. After that show the stock rocketed. Today, it backed down by 8%. A little profit taking I think. Still not to bad. Of course, anytime a stock that I happen to own, jumps I'm not complaining. Granted, there was no actual news from the company that caused the stock to surge in price. A price should be based on how a trader thinks a company will fair. General consensus bridged with viable news reports on the company's or sector's status manifests the stock's price. That would usually mean there will not be a dramatic reverse slide, as it happened today. There should be a company news release, historically speaking, in less than a month. It will most likely consist of the present findings in the T-20 and perhaps T-1249. I do feel that will legitimately push the stock price higher.I will say this, based on price comparison to other companies developing similar drugs going through FDA Phase III tests, the stock is markedly under priced.The company is great, it's management is focused, and the products, if successful, are a gold mine. That gold mine not only benefits the people who are fighting off that fatally traumatic illness with new revolutionary drug treatments, but also benefits it's stock holders.I hold my head up proud and say 'That is a win/win relationship.'
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat